- Contact Us
- Get involved
Great Ormond Street Hospital Charity and Sparks have announced a national funding call in child health research. Under this funding call up to £2M is available to support project grants from researchers across the UK. The emphasis of this call is on complex childhood illness, including rare diseases and we are delighted to announce that this year again, they have partnered with 5 rare disease charities, including Myotubular Trust. Therefore, within this call they are specifically asking for applications that aim to significantly advance the search to find a cure and/or a treatment for any of the genetic forms of centronuclear and myotubular myopathy.
All projects must aim to improve understanding and/or outcomes for the child and have the potential to lead to the development of new diagnostic tools and novel interventions. Proposals will be asked to articulate a clear route to clinical application and strong partnership between clinical and laboratory- based research.
Read more details here: GOSH Charity and Sparks Call for Applications 2019_2020 & FAQ. The deadline for submission of outline applications is 4pm on Thursday 25 July 2019. This funding call particularly encourages applications from early career researchers and those who are still consolidating their independent research careers. They welcome international collaboration and co-operation too.
We are proud to be part of a partnership with these two organisations who have done so much to further the health of children, and we thank all our donors and fundraisers who make it possible for us to be part of such a partnership.
The Myotubular Trust (Registered Charity No: 1137177) was set up in 2006 to raise money for research to find a cure and / or treatment for myotubular myopathy.
The Myotubular Trust has a Scientific Advisory Board (SAB), chaired by Professor Francesco Muntoni of The Institute of Child Health, University College London. The SAB makes recommendations to the Myotubular Trust Trustees on which projects to fund based on scientific merit and peer review.
We are delighted to announce our 2019 call for grants.
As before, we are looking to fund further projects that will help find a cure and / or a treatment for any form of centronuclear and myotubular myopathy (congenital X-linked recessive; congenital autosomal recessive; autosomal dominant), focusing on research that would not generally be funded by public or industrial funding sources. This call will be open to international applications.
Applications may be made for:
1. Project grants
We will consider applications from the Principal Investigator for projects of 2-3 years duration to be carried out by a Post-Doctoral researcher, or PHD student
2. A Myotubular Trust fellowship, non-clinical
Applicants will have identified a host institution and will be undertaking a basic science project of 3-4 years duration
In particular we would like to encourage the application of new technologies to research into centronuclear and myotubular myopathy; interventional trials; and those which may involve collaboration between different medical disciplines and / or different research institutions. We are also willing to consider applications which involve joint funding of new projects with other organisations.
We will require completed applications by 1700 hours GMT Friday 15th March 2019. We anticipate making awards in late June / early July.
Please download an application form here:
Over the years, we have awarded research grants / fellowships for the following projects:
Gene therapy for x-linked myotubular myopathy and pathophysiology – Dr Ana Buj Bello, Genethon, Evry, France – £102,290 over 2 years
Membrane trafficking and T tubule structure and function in a canine model of centronuclear myopathies – Dr Richard Piercy, Royal Veterinary College, London – £38,548 over 3 years
Deciphering the molecular pathway involving centronuclear myopathy genes – Manuela D’Alessandro, IGBMC, Illkirch, France – £120,000 over 3 years
Gene therapy for autosomal dominant centronuclear myopathy by Transplicing – Dr Marc Bitoun, INSERM, Paris – £102,340 over 2 years
Next generation sequencing to tackle centronuclear myopathies – Dr Jocelyn Laporte, IGBMC, France – £62,000 over 2 years
Secondary pathogenic mechanisms in XLMTM and CNM – Dr Susan Treves, Basel University Hospital, Basel, Switzerland and Professor Heinz Jungbluth, King’s College London – £116,664 over 3 years
Pre-clinical gene replacement therapy for X-linked myotubular myopathy (MTM1) – Dr Anna Buj Bello, Genethon, Evry, France – £110,300 over 2 years
Reducing DNM2 as a novel therapeutic target for centronuclear myopathy – Dr Jocelyn Laporte, IGBMC, France – £132,000 over 3 years
PI3 Kinase inhibition as a novel treatment strategy for myotubular myopathy (MTM1) – Dr James Dowling, Hospital for Sick Children, Toronto, Canada – £102,500 over 2 years
Myotubular and Centronuclear Myopathy Patient Registry curation – Professor Hanns Lochmueller, TREAT-NMD, John Walton Muscular Dystrophy Research Centre, Newcastle University – £60,744 over 2 years
Combinatorial therapy as a novel treatment strategy for myotubular myopathy (MTM1) – Dr James Dowling, Hospital for Sick Children, Toronto, Canada – £216,000 over 3 years
Please feel free to download the pdf explaining more about the Myotubular Trust’s research selection process.